Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 14, 2010

CHDI Pledges $37.5M in Research Funding Over the Next Three Years to Evotec

  • Evotec and the CHDI Foundation extended their Huntington disease therapeutics collaboration through to the end of 2012. The extension will provide Evotec with up to $37.5 million in research funding over the next three years.

    The organizations initiated their Huntington-focused partnership in March 2006 and have since signed four agreements covering medicinal chemistry, assay development, and screening along with library synthesis and management services. 

    Evotec is applying its biological science expertise to develop assays such as those designed for high-content screening against high-priority biological targets that are believed to be relevant to the future treatment of Huntington Disease for CHDI and the High Q Foundation.


Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »